KRAS and colorectal carcinoma: Potency and selectivity of ADT-007 to inhibit CRC cell growth were initially determined using two KRAS-mutant and two RAS WT human CRC cell lines grown in monolayer culture following 3 days of treatment and measured using the CellTiter-Glo luminescence assay.